Treatment of sepsis in the surgical intensive care unit

Israel Medical Association Journal

Volumn 13, Issue 11, 2011, Pages 694-699

  Carney, Daniel E ^a   Matsushima, Kazuhide ^b   Frankel, Heidi L ^c  

^a WellSpan Health   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c R ADAMS COWLEY SHOCK TRAUMA CENTER   (United States)

Author keywords

Glucose control; Intensive care unit (ICU); Parenteral nutrition; Sepsis; Steroids

Indexed keywords

ACTIVATED PROTEIN C; CORTICOSTEROID; DROTRECOGIN; FLUDROCORTISONE; GLUCOSE; HYDROCORTISONE; INSULIN; STEROID;

ABSENCE OF SIDE EFFECTS; BLEEDING; BLOOD GLUCOSE MONITORING; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN INFUSION; INTENSIVE CARE UNIT; LOW DRUG DOSE; MORTALITY; PARENTERAL NUTRITION; POSTOPERATIVE COMPLICATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEPSIS; SEPTIC SHOCK;

ADRENAL CORTEX HORMONES; ANTI-INFECTIVE AGENTS; BLOOD GLUCOSE; HUMANS; INTENSIVE CARE UNITS; PARENTERAL NUTRITION; PRACTICE GUIDELINES AS TOPIC; PROTEIN C; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; SEPSIS;

EID: 80755125910     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Barie PS, Williams MD, McCollam JS, et al. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 2004; 188: 212-20.
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10.
3. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996; 312: 71-2.
4. Price J, Ekleberry A, Grover A, et al. Evaluation of clinical practice guidelines on outcome of infection in patients in the surgical intensive care unit. Crit Care Med 1999; 27: 2118-24.
5. Cook DJ, Guyatt GH, Laupacis A, Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992; 102 (4 Suppl): 305-11S.
6. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32: 858-73.
7. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30: 536-55.
8. Eichacker PQ, Danner RL, Suffredini AF, et al. Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial. Crit Care Med 2005; 33: 2426-8.
9. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 2006; 129: 174-81.
10. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
11. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34: 17-60.
12. Rady MY, Johnson DJ, Patel BM, et al. Influence of individual characteristics on outcome of glycemic control in intensive care unit patients with or without diabetes mellitus. Mayo Clin Proc 2005; 80: 1558-67.
13. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355: 773-8.
14. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001; 32: 2426-32.
15. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-67.
16. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 2003; 31: 359-66.
17. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA 2003; 290: 2041-7.
18. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449-61.
19. Scalea TM, Bochicchio GV, Bochicchio KM, et al. Tight glycemic control in critically injured trauma patients. Ann Surg 2007; 246: 605-10; discussion 610-12.
20. Sperry JL, Frankel HL, Vanek SL, et al. Early hyperglycemia predicts multiple organ failure and mortality but not infection. J Trauma 2007; 63: 487-93.
21. Preiser JC, Devos P, Ruiz-Santana S, et al. A prospective randomised multicentre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med 2009; 35: 1738-48.
22. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-39.
23. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-97.
24. Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of highdose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-8.
25. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26: 645-50.
26. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-71.
27. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111-24.
28. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
29. Barkun J, Christou NV; CAGS Evidence Based Reviews in Surgery Group. Canadian Association of General Surgeons Evidence Based Reviews in Surgery. 8. Efficacy and safety of recombinant human activated protein C for severe sepsis. Can J Surg 2003; 46: 468-70.
30. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353: 1332-41.
31. Dudrick SJ, Wilmore DW, Vars HM, Rhoads JE. Long-term total parenteral nutrition with growth, development, and positive nitrogen balance. Surgery 1968; 64: 134-42.
32. Gramlich L, Kichian K, Pinilla J, et al. Does enteral nutrition compared to parenteral nutrition result in better outcomes in critically ill adult patients? A systematic review of the literature. Nutrition 2004; 20: 843-8.
33. Kalfarentzos F, Kehagias J, Mead N, et al. Enteral nutrition is superior to parenteral nutrition in severe acute pancreatitis: results of a randomized prospective trial. Br J Surg 1997; 84: 1665-9.
34. Kudsk KA, Croce MA, Fabian TC, et al. Enteral versus parenteral feeding. Effects on septic morbidity after blunt and penetrating abdominal trauma. Ann Surg 1992; 215: 503-11.
35. Peter JV, Moran JL, Phillips-Hughes J. A meta-analysis of treatment outcomes of early enteral versus early parenteral nutrition in hospitalized patients. Crit Care Med 2005; 33: 213-20.
36. Matsushima K, Cook AD, Tyner T, et al. Parenteral nutrition: a clear and present danger unabated by tight glucose control. Am J Surg, in press.
37. Sena MJ, Utter GH, Cuschieri J, et al. Early supplemental parenteral nutrition is associated with increased infectious complications in critically ill trauma patients. J Am Coll Surg 2008; 207: 459-67.
38. Singer P, Berger MM, Van den Berghe G, et al. ESPEN Guidelines on Parenteral Nutrition: intensive care. Clin Nutr 2009; 28: 387-400.